Optima Capital’s United Therapeutics UTHR Stock Holding History

Optima Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5	Closed	-$2.44K	–	1239
2025 Q4	$2.44K	Buy	+5	New	+$2.33K	﹤0.01%	728

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Optima Capital's UTHR Position: Q1 2026 in Review

Optima Capital sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 5 shares — an estimated $2.44K sold.

Optima Capital first reported a position in UTHR in Q4 2025 and held it in 1 quarter. The position peaked at $2.44K in Q4 2025. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Optima Capital reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 5 United Therapeutics shares in Q1 2026, an estimated $2.44K.
Optima Capital first reported a position in United Therapeutics in Q4 2025 and held it in 1 quarter.
Optima Capital's United Therapeutics position peaked at $2.44K in Q4 2025.
851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.